Skip to content

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01746303
Enrollment
94
Registered
2012-12-10
Start date
2010-01-31
Completion date
2016-01-31
Last updated
2016-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related Memory Disorders, Mood Disorders

Keywords

Working memory, Long-term memory, Neurocognition, Dietary supplementation, dementia

Brief summary

The aim of this study is to determine the efficacy of 6 months' dietary supplementation with omega-3 fatty acids and whole freeze dried blueberry powder in improving cognition in older adults. The effects of each of these interventions alone will also be assessed in order to determine whether the combined treatment confers synergistic or additive benefit relative to the effect of each therapy.

Detailed description

After meeting inclusion criteria, one hundred-forty men and women, aged 62 to 80 years old, will be enrolled and randomly assigned to one of four groups: 1) omega-3 fatty acid and blueberry powder supplement, 2) omega-3 fatty acid and placebo powder, 3) placebo oil and blueberry powder supplement, or 4) placebo oil and placebo powder. They will participate in a 24-week intervention with major assessments including neuropsychological and functional evaluation at pre-treatment baseline and during the final week of the intervention. In addition, an interim evaluation of neurocognitive function will be conducted at 12 weeks. Subjects will be asked to maintain diet diaries for three periods during the study. Mood will be assessed as a potential covariate of the neurobehavioral outcome measures and data on red blood cell fatty acid content, metabolic parameters, inflammation, and anthropometric factors will be gathered to assess compliance and explore individual differences in response to the intervention and to evaluate potential mechanisms of action.

Interventions

DIETARY_SUPPLEMENTOmega-3 fatty acid

A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).

DIETARY_SUPPLEMENTBlueberry powder

Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.

OTHERPlacebo oil

Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.

OTHERPlacebo powder

Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.

Sponsors

University of Cincinnati
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
62 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* men and women aged 62 to 80 years and older * age-associated decline operationalized as Clinical Dementia Rating = 0, Auditory Verbal Learning Test cumulative acquisition score between 1.0 standard deviation below and 1.0 standard deviation above the age-corrected mean or Montreal Cognitive Assessment score greater than 25, and Geriatric Depression Scale score less than 16 * ability to comprehend and comply with the research protocol * provision of written informed consent.

Exclusion criteria

* established dementia or neurological disorder including but not limited to probable Alzheimer's Disease, Parkinson's Disease, Frontotemporal dementia, multi-infarct dementia, and leukoencephalopathy * current or past severe psychiatric disorder such as psychosis or major mood disorder requiring hospitalization and/or causing a change in level of occupational or social functioning * current or past alcohol or drug abuse disorder causing physiological dependence or change in functional capability (nicotine dependence is permitted) * diagnosis of diabetes or other metabolic disorder or kidney or liver disease * use of medication that might affect outcome measures or interact with omega 3 fatty acid supplements such as benzodiazepines, aspirin, and serotonin reuptake inhibitors * hematological coagulation disorder * allergy to shellfish or seafood; 8) current supplementation with fish oil or consumption of fish more than once per week.

Design outcomes

Primary

MeasureTime frameDescription
Working Memory and Executive Ability6 monthsThe following tests will be administered to measure working memory function: * Porteus Maze Test * Verbal Primary Memory with Interference Test * Letter Number Sequencing Task * Controlled Oral Word Production Task

Secondary

MeasureTime frameDescription
Mood Assessment6 monthsThe following scale will be used to assess mood: * Geriatric Depression Scale * Geriatric Anxiety Inventory
Daily Functioning Assessment6 monthsThe following scale will be used to measure daily functioning: \- Older Americans Resources and Services Functional Assessment Questionnaire
Long-term memory function6 monthsThe following assessments will be conducted to measure Long-term memory function: * California Verbal Learning Test, Second Edition * Visual Nonverbal Recognition Memory Test * Verbal Paired Associate Learning Task * Spatial Paired Associate Learning Task

Other

MeasureTime frameDescription
Ancillary Measures6 monthsThe following measures will be collected: * Red blood cell fatty acid composition * Inflammatory and metabolic parameters * Waist Circumference, Hip Circumference, Height, Body Weight, Blood pressure, Heart rate * Urinary anthocyanin studies * Diet Diaries

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026